0001567619-21-017206.txt : 20210916 0001567619-21-017206.hdr.sgml : 20210916 20210916174314 ACCESSION NUMBER: 0001567619-21-017206 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210914 FILED AS OF DATE: 20210916 DATE AS OF CHANGE: 20210916 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KLARMAN SETH A CENTRAL INDEX KEY: 0000899869 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38550 FILM NUMBER: 211258775 BUSINESS ADDRESS: BUSINESS PHONE: 6172108300 MAIL ADDRESS: STREET 1: 10 ST JAMES AVENUE STREET 2: STE 1700 CITY: BOSTON STATE: MA ZIP: 02116 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Baupost Group GP, L.L.C. CENTRAL INDEX KEY: 0001738693 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38550 FILM NUMBER: 211258776 BUSINESS ADDRESS: STREET 1: 10 ST. JAMES AVENUE STREET 2: SUITE 1700 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617-210-8300 MAIL ADDRESS: STREET 1: 10 ST. JAMES AVENUE STREET 2: SUITE 1700 CITY: BOSTON STATE: MA ZIP: 02116 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BAUPOST GROUP LLC/MA CENTRAL INDEX KEY: 0001061768 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38550 FILM NUMBER: 211258777 BUSINESS ADDRESS: STREET 1: 10 ST JAMES AVE STREET 2: SUITE 1700 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617-210-8300 MAIL ADDRESS: STREET 1: 10 ST JAMES AVE STREET 2: SUITE 1700 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Translate Bio, Inc. CENTRAL INDEX KEY: 0001693415 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 611807780 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-945-7361 MAIL ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: RaNA Therapeutics, Inc. DATE OF NAME CHANGE: 20161228 4/A 1 doc1.xml FORM 4/A X0306 4/A 2021-09-14 2020-06-30 0 0001693415 Translate Bio, Inc. TBIO 0001061768 BAUPOST GROUP LLC/MA 10 ST. JAMES AVENUE SUITE 1700 BOSTON MA 02116 0 0 1 0 0001738693 Baupost Group GP, L.L.C. 10 ST. JAMES AVENUE SUITE 1700 BOSTON MA 02116 0 0 1 0 0000899869 KLARMAN SETH A 10 ST. JAMES AVENUE SUITE 1700 BOSTON MA 02116 0 0 1 0 Common Stock 2021-09-14 4 J 0 18044239 38 D 0 I See footnote 1 and 2 This statement on Form 4 is being jointly filed by The Baupost Group, L.L.C. ("Baupost"), Baupost Group GP, L.L.C. ("BG GP") and Seth A. Klarman ("Mr. Klarman") (collectively, the "Reporting Persons"). Baupost is a registered investment adviser. The principal business of Baupost is to act as an investment adviser to various private investment limited partnerships. BG GP, as the manager of Baupost, and Mr. Klarman, as the sole managing member of BG GP and a controlling person of Baupost, may be deemed to have beneficial ownership under Section 13 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), of the securities beneficially owned by Baupost. Securities reported on this Form 4 as being beneficially owned by Baupost were purchased on behalf of certain of such partnerships. (Continued from Footnote 1) The Reporting Persons disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that the Reporting Persons are the beneficial owners thereof for purposes of Section 16 of the Exchange Act or for any other purpose. On September 14, 2021, the Agreement and Plan of Merger among Sanofi, Vector Merger Sub Inc. and Translate Bio Inc. ("Merger Agreement") was consummated and Sanofi completed its acquisition of the Issuer as described in the 8-K filed by the Issuer on September 14, 2021, and incorporated herein by reference. In connection with the consummation of the merger, all shares of Common Stock of the Issuer held by the Reporting Persons were acquired at the tender offer price of $38.00 per share. Seth A. Klarman 2021-09-16 Seth A. Klarman 2021-09-16 Seth A. Klarman 2021-09-16